Infectious Disease

Tocilizumab could decrease the chance of COVID-19 development, however not mortality

17th December 2020

2 min read

Source / information

Disclosure:
Salama reports personal fees from Genentech outside of the submitted work. In the study you will find all relevant financial information from all other authors.

ADD SUBJECT TO EMAIL ALARMS

Receive an email when new articles are published

Please enter your email address to receive an email when new articles are published . “data-action =” subscribe “> subscribe

We could not process your request. Please try again later. If you continue to have this problem, please contact customerservice@slackinc.com.

Back to Healio

Tocilizumab may reduce the likelihood of mechanical ventilation in patients with COVID-19 pneumonia, but not the risk of death. This is evident from research published in the New England Journal of Medicine.

“Tocilizumab, an anti-interleukin-6 receptor monoclonal antibody, has been approved for the treatment of multiple inflammatory diseases and appeared to improve outcomes in patients with COVID-19 pneumonia in observational studies in the US and worldwide.” Carlos Salama, MD Associate Professor of Medicine at the Icahn School of Medicine and Mount Sinai Hospital, and colleagues wrote. “However, randomized studies of tocilizumab have shown mixed results in patients with varying degrees of COVID-19 disease severity and in populations with different background standards of treatment.”

Tocilizumab may reduce the likelihood of mechanical ventilation in patients with COVID-19 pneumonia, but not the risk of death. This is evident from research published in the New England Journal of Medicine. Source: Adobe Stock.

Salama and colleagues conducted a randomized, double-blind, placebo-controlled phase 3 study evaluating the safety and effectiveness of tocilizumab (Actemra, Genentech) in patients with COVID-19 pneumonia without ventilation.

The researchers enrolled patients from the United States, Mexico, Kenya, South Africa, Peru, and Brazil. Study locations were selected based on their enrollment from high risk or minority populations.

Participants were randomly given 2: 1 intravenous tocilizumab in addition to standard care or placebo with standard care. The researchers evaluated the results on day 28 and followed up the patients through day 60.

A total of 389 patients were randomized, 56% of whom were Hispanic or Latino, 14.9% black, 12.7% Native American or Native to Alaska, and 12.7% white.

Among the participants, 225 of the tocilizumab group and 115 of the placebo group completed the study and were included in the analyzes.

Salama and colleagues found that the cumulative percentage of participants who received mechanical ventilation or who died on day 28 was 12% (95% CI, 8.5 to 16.9) in the tocilizumab group and 19.3% ( 95% CI, 13.3-27.4) was the placebo group (HR = 0.56; 95% CI, 0.33 to 0.97).

On day 28, 10.4% of patients who received tocilizumab experienced death from any cause compared with 8.6% of patients who received placebo (weighted difference = 2 percentage points; 95% CI, -5.2 to 7.8).

Serious adverse events were seen in 15.2% of patients given tocilizumab and 19.7% of patients given placebo, according to Salama and colleagues.

“Our study showed that tocilizumab plus standard treatment was more effective than placebo plus standard treatment at reducing the likelihood of a combined mechanical ventilation outcome or death in hospitalized patients with COVID-19 pneumonia who were not receiving mechanical ventilation. However, there was no difference in the incidence of death from any cause, ”wrote Salama and colleagues, adding that the reduced risk of mechanical ventilation was observed in patients who are typically underrepresented in clinical trials.

ADD SUBJECT TO EMAIL ALARMS

Receive an email when new articles are published

Please enter your email address to receive an email when new articles are published . “data-action =” subscribe “> subscribe

We could not process your request. Please try again later. If you continue to have this problem, please contact customerservice@slackinc.com.

Back to Healio

COVID-19 Resource Center

COVID-19 Resource Center

Related Articles